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OBJECTIVES: Health-policy observers increasingly view budget
impact as an important factor in drug reimbursement decisions.
In a number of instances budget impact seems to have been a
more decisive factor than cost-effectiveness in determining a
drug’s formulary placement. Nevertheless, budget impact usually
is an implicit factor in the decision-making process, while cost-
effectiveness is an explicitly deﬁned criterion. The objective of
our research is to summarize possible arguments supporting the
use of budget impact as a criterion in drug reimbursement deci-
sions, and to inform the debate on whether budget impact can be
legitimately (and explicitly) used in reimbursement decision-
making. METHODS: Based on a literature review spanning
1990 to 2006, we traced a variety of deﬁnitions of budget impact
as well as rationales supporting its use. Furthermore, we con-
ducted supplementing interviews with 15 key stakeholders
involved in drug reimbursement decisions in The Netherlands.
RESULTS: We found that policymakers employ several deﬁni-
tions of budget impact that differ mainly in terms of their scope.
However, policymakers did not reveal rationales that would
support the use of budget impact in drug reimbursement deci-
sions. Nonetheless, in health economics and policy literature, we
identiﬁed ﬁve types of supporting rationales: “losing out”
(opportunity cost), uncertainty regarding return on investment,
equal access, equal opportunity and “loss outweighing gain.”
CONCLUSION: Budget impact is a legitimate rationing crite-
rion, though its precise use, explicit or implicit, in policy practice
remains unclear. We recommend that policymakers not conﬂate
budget impact and cost-effectiveness arguments. Further, we rec-
ommend that health economists and policymakers be aware that
incremental cost-effectiveness ratios (ICERs) are of limited value
in resolving the problem of maximizing subject to health gain, as
ICERs fail to account for opportunity cost and ignore the impor-
tant question of how many resources need to be set aside to fund
adoption of newly approved cost-effective biopharmaceuticals.
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OBJECTIVES: To determine the prevalence of polypharmacy
and the explanation power of Adjusted Clinical Groups (ACG)
classiﬁcation as a measure of morbidity burden in a Spanish
population setting. METHODS: Cross-sectional study based on
the clinical records from all the attended patients in ﬁve primary
care centres along the year 2006. Main variables: age, sex, case-
mix/episodes, pharmacy costs, therapeutic group, polypharmacy
(regular utilization of more than 5 drugs at least 240 days/year),
explained variance (predictive analysis and multiple linear regres-
sion). The ACG (Johns-Hopkins Case-mix System) classify indi-
viduals with similar needs for health care resources based on
overall expenditures. For analysis purposes, the ACG are col-
lapsed to one of eight mutually exclusive morbidity classes,
known as resource utilization bands (RUB) (collapsed: Low-
Comorbidity, Medium-Comorbidity and High-Comorbidity).
Logistic regression and ANCOVA (Bonferroni adjustment)
analysis were made to adjust the models. The statistical package
SPSS was used (p < 0.05). RESULTS: Included patients: 80,775.
Average number of episodes: 4.83.5; mean age: 40.722.9
years, males: 46.9%, intensity of use: 72.4%, pharmacy costs:
€22.7 millions (55.6% of total costs) and mean cost:
€281.05627.85. Polypharmacy prevalence was 12.2% (CI:
12.0–12.4%), increasing with age (50,1%; in >85 years), female
sex and morbidity burden (Low-Comorbidity [16.5%]: 1.1%,
Medium-Comorbidity [78.3%]: 11.8% and High-Comorbidity
[5.2%]: 40.3%), p < 0.0001. A strong association was observed
with alcoholism, asthma, depression, and digestive and cardio-
vascular therapeutic groups (OR > 4.3, p < 0.0001). Predictive
and regression analysis: ROC curve (pharmacy costs): 0.968;
sensibility: 96.1%, speciﬁcity: 61.7%, R2 (Nagelkerke): 62.2%;
explained variance: R2 = 26.8%; age, sex, comorbidity model:
R2 = 42.2 (p < 0.001). Individual cost for patients with High-
Comorbidity was €1436.53 and after adjustment was €1047.59
(CI: 1002.87–1092.31). CONCLUSION: The observed polyp-
harmacy proﬁle was similar to others described in the literature.
ACG classiﬁcation provides a fair good explanation of the phar-
macy costs variability after adjustment by age, sex and comor-
bidity (42.2%), including a signiﬁcative share of polypharmacy.
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COMPLEMENT OR SUBSTITUTE? COMPLEMENTARY AND
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OBJECTIVES: To examine the bivariate relationships between
CAM use for treatment of a speciﬁc illness and prescription drug
use among African American adults and to describe the extent of
complementary and substitutive CAM use. METHODS: Using
the 2002 National Health Interview Survey, the data included
4,256 AA adults representing 23,828,268 African American
adults nationwide. Respondents were asked if they used certain
CAM modalities in the past 12 months to treat a speciﬁc condi-
tion. Our study focused on those who used CAM for treatment
and whether or not they also used prescription medication in the
last 12 months. RESULTS: A total of 99.4 percent of African
Americans who used CAM in the past 12 months used at least
one CAM modality to treat a speciﬁc illness. Of these, 77.7%
also used prescription medication during the past 12 months
(complementary CAM users) while 22.3 percent did not (possible
substitutive CAM users). For 13 of the 14 CAM modalities
examined, a majority of CAM for treatment users (60.4 to
100.0%) also used prescription medication. The exception was
folk medicine where 65% did not use prescription medication. A
total of 13.6% of users of mind-body therapies (e.g., relaxation)
were potentially substitutive users compared to 23.0 percent of
manipulative therapy (e.g., massage) users, 25.2% of alternative
medical system (e.g., acupuncture) users, and 25.7% of
biologically-based therapy (e.g., folk medicine, herbals) users.
Complementary CAM users had more medical conditions
(p < 0.0001) and were more likely female (p < 0.0001) and pub-
licly insured (p < 0.0001) compared to possible substitutive
CAM users, who were more likely younger (p < 0.0001) and
better educated (p < 0.01). CONCLUSION: While the majority
of African Americans who use CAM for treatment for a speciﬁc
condition also use prescription medication (complementary
users), more than 20% may substitute CAM for conventional
treatment.
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